|
2026-09-04 |
2026-09-02 |
V
Verkauf
|
EVP, WW Chair, MedTech
Führungsperson
|
1.812
+43.4%
229,72
2.998.866 $
|
1.812
+43.4%
|
229,72
|
2.998.866 $
|
|
|
2026-09-04 |
2026-09-02 |
V
Verkauf
|
EVP, WW Chair, MedTech
Führungsperson
|
31.108
+6.6%
429,96
2.173.148 $
|
31.108
+6.6%
|
429,96
|
2.173.148 $
|
|
|
2026-09-02 |
2026-09-02 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
17.720
294,54
4.500.404 $
|
17.720
|
294,54
|
4.500.404 $
|
|
|
2026-08-18 |
2026-08-17 |
V
Verkauf
|
EVP, WWC. Innovative Medicine
Führungsperson
|
15.000
-7.2%
263,36
3.950.400 $
|
15.000
-7.2%
|
263,36
|
3.950.400 $
|
|
|
2026-08-17 |
2026-08-17 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
15.000
263,36
3.950.418 $
|
15.000
|
263,36
|
3.950.418 $
|
|
|
2026-08-14 |
2026-08-13 |
V
Verkauf
|
CEO and Chairman of the Board
Geschäftsführender Direktor
|
102.315
-27.0%
261,00
26.704.215 $
|
102.315
-27.0%
|
261,00
|
26.704.215 $
|
|
|
2026-08-14 |
2026-08-13 |
V
Verkauf
|
CEO and Chairman of the Board
Geschäftsführender Direktor
|
20.976
-5.3%
262,00
5.495.712 $
|
20.976
-5.3%
|
262,00
|
5.495.712 $
|
|
|
2026-08-13 |
2026-08-13 |
PrS
Geplanter Verkauf
|
Officer; Director
Geschäftsführender Direktor
|
123.291
261,17
32.199.927 $
|
123.291
|
261,17
|
32.199.927 $
|
|
|
2026-08-07 |
2026-08-06 |
V
Verkauf
|
EVP, Chief Legal Officer
Führungsperson
|
6.574
-27.9%
255,93
1.682.497 $
|
6.574
-27.9%
|
255,93
|
1.682.497 $
|
|
|
2026-08-07 |
2026-08-06 |
V
Verkauf
|
EVP, Chief Legal Officer
Führungsperson
|
9.344
-28.4%
257,76
2.408.463 $
|
9.344
-28.4%
|
257,76
|
2.408.463 $
|
|
|
2026-08-06 |
2026-08-06 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
15.918
257,00
4.090.957 $
|
15.918
|
257,00
|
4.090.957 $
|
|
|
2026-08-07 |
2026-08-05 |
V
Verkauf
|
CEO and Chairman of the Board
Geschäftsführender Direktor
|
6.523
-2.3%
258,74
1.687.754 $
|
6.523
-2.3%
|
258,74
|
1.687.754 $
|
|
|
2026-08-07 |
2026-08-05 |
V
Verkauf
|
CEO and Chairman of the Board
Geschäftsführender Direktor
|
41.957
-12.9%
258,06
10.827.256 $
|
41.957
-12.9%
|
258,06
|
10.827.256 $
|
|
|
2026-08-05 |
2026-08-05 |
PrS
Geplanter Verkauf
|
CEO, Chariman
|
48.480
254,93
12.359.006 $
|
48.480
|
254,93
|
12.359.006 $
|
|
|
2026-07-21 |
2026-07-20 |
V
Verkauf
|
EVP, Global Corp Affairs
Führungsperson
|
23.054
-50.1%
251,27
5.792.686 $
|
23.054
-50.1%
|
251,27
|
5.792.686 $
|
|
|
2026-07-20 |
2026-07-20 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
23.054
251,27
5.792.689 $
|
23.054
|
251,27
|
5.792.689 $
|
|
|
2026-06-12 |
2026-06-11 |
V
Verkauf
|
EVP, Chief TO and Risk Officer
Führungsperson
|
10.000
-8.0%
241,15
2.411.500 $
|
10.000
-8.0%
|
241,15
|
2.411.500 $
|
|
|
2026-06-11 |
2026-06-11 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
10.000
240,15
2.401.539 $
|
10.000
|
240,15
|
2.401.539 $
|
|
|
2026-03-03 |
2026-02-27 |
V
Verkauf
|
VP Corporate Controller
Führungsperson
|
4.075
-14.7%
247,87
1.010.070 $
|
4.075
-14.7%
|
247,87
|
1.010.070 $
|
|
|
2026-02-27 |
2026-02-27 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
4.075
247,87
1.010.070 $
|
4.075
|
247,87
|
1.010.070 $
|
|
|
2026-02-23 |
2026-02-20 |
V
Verkauf
|
EVP, WW Chair, MedTech
Führungsperson
|
1.322
-4.9%
245,66
324.763 $
|
1.322
-4.9%
|
245,66
|
324.763 $
|
|
|
2026-02-20 |
2026-02-20 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
1.322
245,66
324.763 $
|
1.322
|
245,66
|
324.763 $
|
|
|
2026-02-18 |
2026-02-18 |
V
Verkauf
|
EVP, WW Chair, MedTech
Führungsperson
|
8.998
-25.2%
244,53
2.200.281 $
|
8.998
-25.2%
|
244,53
|
2.200.281 $
|
|
|
2026-02-18 |
2026-02-18 |
V
Verkauf
|
EVP, WW Chair, MedTech
Führungsperson
|
13.625
-33.7%
244,20
3.327.225 $
|
13.625
-33.7%
|
244,20
|
3.327.225 $
|
|
|
2026-02-18 |
2026-02-18 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
22.623
244,33
5.527.546 $
|
22.623
|
244,33
|
5.527.546 $
|
|
|
2026-02-18 |
2026-02-17 |
V
Verkauf
|
EVP, Innovative Medicine, R&D
Führungsperson
|
2.283
-17.6%
243,00
554.769 $
|
2.283
-17.6%
|
243,00
|
554.769 $
|
|
|
2026-02-18 |
2026-02-17 |
V
Verkauf
|
EVP, Innovative Medicine, R&D
Führungsperson
|
29.927
-69.8%
243,00
7.272.261 $
|
29.927
-69.8%
|
243,00
|
7.272.261 $
|
|
|
2026-02-18 |
2026-02-17 |
V
Verkauf
|
EVP, Innovative Medicine, R&D
Führungsperson
|
21.721
-62.7%
243,00
5.278.203 $
|
21.721
-62.7%
|
243,00
|
5.278.203 $
|
|
|
2026-02-18 |
2026-02-17 |
V
Verkauf
|
Exec VP, CFO
Führungsperson
|
24.961
-64.1%
242,68
6.057.535 $
|
24.961
-64.1%
|
242,68
|
6.057.535 $
|
|
|
2026-02-18 |
2026-02-17 |
V
Verkauf
|
Exec VP, CFO
Führungsperson
|
33.386
-46.1%
242,75
8.104.452 $
|
33.386
-46.1%
|
242,75
|
8.104.452 $
|
|
|
2026-02-18 |
2026-02-17 |
V
Verkauf
|
Exec VP, CFO
Führungsperson
|
12.066
-23.6%
242,87
2.930.469 $
|
12.066
-23.6%
|
242,87
|
2.930.469 $
|
|
|
2026-02-18 |
2026-02-17 |
V
Verkauf
|
Exec VP, CFO
Führungsperson
|
19.241
-33.1%
242,99
4.675.371 $
|
19.241
-33.1%
|
242,99
|
4.675.371 $
|
|
|
2026-02-18 |
2026-02-17 |
V
Verkauf
|
EVP, CIO
Führungsperson
|
20.521
-44.4%
242,70
4.980.447 $
|
20.521
-44.4%
|
242,70
|
4.980.447 $
|
|
|
2026-02-18 |
2026-02-17 |
V
Verkauf
|
EVP, Global Corp Affairs
Führungsperson
|
6.197
-21.2%
243,39
1.508.288 $
|
6.197
-21.2%
|
243,39
|
1.508.288 $
|
|
|
2026-02-17 |
2026-02-17 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
6.197
243,39
1.508.300 $
|
6.197
|
243,39
|
1.508.300 $
|
|
|
2026-02-17 |
2026-02-17 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
20.521
242,70
4.980.510 $
|
20.521
|
242,70
|
4.980.510 $
|
|
|
2026-02-17 |
2026-02-17 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
89.654
242,80
21.767.965 $
|
89.654
|
242,80
|
21.767.965 $
|
|
|
2026-02-17 |
2026-02-17 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
53.931
243,00
13.105.233 $
|
53.931
|
243,00
|
13.105.233 $
|
|
|
2026-02-18 |
2026-02-13 |
V
Verkauf
|
EVP, CIO
Führungsperson
|
22.191
-47.0%
243,71
5.408.169 $
|
22.191
-47.0%
|
243,71
|
5.408.169 $
|
|
|
2026-02-18 |
2026-02-13 |
V
Verkauf
|
EVP, CIO
Führungsperson
|
19.368
-43.6%
243,76
4.721.144 $
|
19.368
-43.6%
|
243,76
|
4.721.144 $
|
|
|
2026-02-13 |
2026-02-13 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
41.559
243,73
10.129.246 $
|
41.559
|
243,73
|
10.129.246 $
|
|
|
2026-02-05 |
2026-02-05 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
6.226
237,90
1.481.195 $
|
6.226
|
237,90
|
1.481.195 $
|
|
|
2026-01-28 |
2026-01-26 |
V
Verkauf
|
CEO and Chairman of the Board
Geschäftsführender Direktor
|
48.782
-61.3%
221,48
10.804.432 $
|
48.782
-61.3%
|
221,48
|
10.804.432 $
|
|
|
2026-01-28 |
2026-01-26 |
V
Verkauf
|
CEO and Chairman of the Board
Geschäftsführender Direktor
|
51.218
-39.1%
220,99
11.318.461 $
|
51.218
-39.1%
|
220,99
|
11.318.461 $
|
|
|
2026-01-26 |
2026-01-26 |
PrS
Geplanter Verkauf
|
CEO, Chariman
|
100.000
220,14
22.014.000 $
|
100.000
|
220,14
|
22.014.000 $
|
|
|
2025-12-01 |
2025-11-26 |
K
Kauf
|
Nicht geschäftsführender Verwaltungsratsmitglied
|
1.250
+208.9%
206,15
257.688 $
|
1.250
+208.9%
|
206,15
|
257.688 $
|
|
|
2025-10-20 |
2025-10-17 |
V
Verkauf
|
EVP, Innovative Medicine, R&D
Führungsperson
|
21.721
-67.1%
192,71
4.185.793 $
|
21.721
-67.1%
|
192,71
|
4.185.793 $
|
|
|
2025-10-17 |
2025-10-17 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
21.721
192,71
4.185.794 $
|
21.721
|
192,71
|
4.185.794 $
|
|
|
2025-09-05 |
2025-09-04 |
V
Verkauf
|
EVP, WWC. Innovative Medicine
Führungsperson
|
56.471
-24.1%
177,81
10.040.883 $
|
56.471
-24.1%
|
177,81
|
10.040.883 $
|
|
|
2025-09-04 |
2025-09-04 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
56.471
177,81
10.040.904 $
|
56.471
|
177,81
|
10.040.904 $
|
|
|
2025-08-29 |
2025-08-29 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
9.570
177,20
1.695.806 $
|
9.570
|
177,20
|
1.695.806 $
|
|
|
2025-08-25 |
2025-08-22 |
V
Verkauf
|
CEO and Chairman of the Board
Geschäftsführender Direktor
|
125.824
-31.3%
179,21
22.548.655 $
|
125.824
-31.3%
|
179,21
|
22.548.655 $
|
|
|
2025-08-22 |
2025-08-22 |
PrS
Geplanter Verkauf
|
Officer; Director
Geschäftsführender Direktor
|
125.824
180,04
22.652.724 $
|
125.824
|
180,04
|
22.652.724 $
|
|
|
2025-08-18 |
2025-08-15 |
V
Verkauf
|
Exec VP, CFO
Führungsperson
|
16.820
-54.6%
176,91
2.975.571 $
|
16.820
-54.6%
|
176,91
|
2.975.571 $
|
|
|
2025-08-15 |
2025-08-15 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
16.820
176,91
2.975.571 $
|
16.820
|
176,91
|
2.975.571 $
|
|
|
2025-07-18 |
2025-07-17 |
V
Verkauf
|
EVP, Innovative Medicine, R&D
Führungsperson
|
19.137
-64.2%
163,55
3.129.830 $
|
19.137
-64.2%
|
163,55
|
3.129.830 $
|
|
|
2025-07-17 |
2025-07-17 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
19.137
163,55
3.129.831 $
|
19.137
|
163,55
|
3.129.831 $
|
|
|
2025-02-26 |
2025-02-25 |
V
Verkauf
|
VP Corporate Controller
Führungsperson
|
6.999
-25.0%
165,88
1.160.994 $
|
6.999
-25.0%
|
165,88
|
1.160.994 $
|
|
|
2025-02-25 |
2025-02-25 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
6.999
165,88
1.161.010 $
|
6.999
|
165,88
|
1.161.010 $
|
|
|
2025-02-18 |
2025-02-18 |
V
Verkauf
|
EVP, WW Chair, MedTech
Führungsperson
|
403
-2.6%
156,15
62.928 $
|
403
-2.6%
|
156,15
|
62.928 $
|
|
|
2025-02-11 |
2025-02-07 |
V
Verkauf
|
Exec VP, CFO
Führungsperson
|
13.015
-100.0%
153,89
2.002.878 $
|
13.015
-100.0%
|
153,89
|
2.002.878 $
|
|
|
2025-02-07 |
2025-02-07 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
13.015
153,89
2.002.924 $
|
13.015
|
153,89
|
2.002.924 $
|
|
|
2024-12-12 |
2024-12-12 |
K
Kauf
|
Nicht geschäftsführender Verwaltungsratsmitglied
|
1.000
+inf%
147,22
147.220 $
|
1.000
+inf%
|
147,22
|
147.220 $
|
|
|
2024-12-04 |
2024-12-04 |
PrS
Geplanter Verkauf
|
Former Officer
Führungsperson
|
25.742
149,90
3.858.598 $
|
25.742
|
149,90
|
3.858.598 $
|
|
|
2024-09-03 |
2024-08-30 |
V
Verkauf
|
VP Corporate Controller
Führungsperson
|
5.635
-22.9%
165,06
930.113 $
|
5.635
-22.9%
|
165,06
|
930.113 $
|
|
|
2024-08-30 |
2024-08-30 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
5.635
165,06
930.113 $
|
5.635
|
165,06
|
930.113 $
|
|
|
2024-03-13 |
2024-03-13 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
8.891
162,16
1.441.732 $
|
8.891
|
162,16
|
1.441.732 $
|
|
|
2024-03-13 |
2024-03-13 |
V
Verkauf
|
EVP, Global Corp Affairs
Führungsperson
|
8.891
-37.1%
162,16
1.441.765 $
|
8.891
-37.1%
|
162,16
|
1.441.765 $
|
|
|
2024-02-12 |
2024-02-09 |
V
Verkauf
|
EVP, WW Chair, Pharmaceuticals
Führungsperson
|
59.397
-29.6%
156,27
9.281.969 $
|
59.397
-29.6%
|
156,27
|
9.281.969 $
|
|
|
2024-02-09 |
2024-02-09 |
PrS
Geplanter Verkauf
|
Former Officer
Führungsperson
|
24.613
156,50
3.851.866 $
|
24.613
|
156,50
|
3.851.866 $
|
|
|
2024-02-09 |
2024-02-09 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
59.397
156,25
9.280.528 $
|
59.397
|
156,25
|
9.280.528 $
|
|
|
2024-02-06 |
2024-02-06 |
PrS
Geplanter Verkauf
|
FORMER OFFICER
Führungsperson
|
24.612
157,88
3.885.716 $
|
24.612
|
157,88
|
3.885.716 $
|
|
|
2023-07-27 |
2023-07-26 |
V
Verkauf
|
See Remarks
Führungsperson
|
14.698
-14.3%
172,00
2.528.056 $
|
14.698
-14.3%
|
172,00
|
2.528.056 $
|
|
|
2023-07-26 |
2023-07-26 |
PrS
Geplanter Verkauf
|
Officer
Führungsperson
|
14.698
172,00
2.528.056 $
|
14.698
|
172,00
|
2.528.056 $
|
|
|
2023-07-27 |
2023-07-25 |
V
Verkauf
|
Exec VP, Chief HR Officer
Führungsperson
|
20.000
-16.3%
170,32
3.406.498 $
|
20.000
-16.3%
|
170,32
|
3.406.498 $
|
|